{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T04:01:21Z","timestamp":1774584081207,"version":"3.50.1"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Pituitary pars intermedia dysfunction (PPID) is the most prevalent endocrine disorder of older equids. To date, key research areas likely to have the greatest impact on equine health have not been identified. In human medicine, public and patient involvement is widely used to inform research agendas. This study aimed to engage with veterinary surgeons and horse owners to identify evidence gaps (\u2018uncertainties\u2019) and prioritise these into a list of the 10 most important PPID research questions. The James Lind Alliance (JLA) Priority Setting Partnership (PSP) Framework was adapted. Questions about the diagnosis, treatment and prognosis of PPID were gathered via an online survey targeting veterinary surgeons and horse owners with experience of PPID. Thematic analysis was used to form a longlist of collated indicative research questions (CIRQs), defined by the JLA as true \u2018evidence uncertainties\u2019 when not answered by a published, clinically relevant, up-to-date systematic review. In an interim prioritisation survey, questions were ranked by weighted scores creating a shortlist of 25 that were taken forward to the PSP workshop, where participants reached a consensus on the top 10. Useable responses containing \u22651 question were received from 524 respondents (92.6% owners, n = 485; 7.4% veterinary surgeons, n = 39). After screening for relevance, 1,260 individual questions were included in thematic analysis, resulting in 47 CIRQs. Interim prioritisation votes for the CIRQs were received from 360 respondents. The top 10 questions prioritised at the PSP workshop focused on long-term prognosis, diagnostic accuracy, efficacy of pergolide treatment, alternative treatment\/management strategies and potential treatment options for poor responders to pergolide. The quantity of questions generated indicates an extensive number of uncertainties regarding the diagnosis, treatment and prognosis of PPID. The top 10 research questions will help to inform key areas for evidence synthesis and knowledge translation, and to direct future research into areas most important to end users involved in caring for and treating animals with PPID.<\/jats:p>","DOI":"10.1371\/journal.pone.0244784","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T23:07:17Z","timestamp":1609801637000},"page":"e0244784","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Equine pituitary pars intermedia dysfunction: Identifying research priorities for diagnosis, treatment and prognosis through a priority setting partnership"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2136-3807","authenticated-orcid":true,"given":"Rebecca C.","family":"Tatum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy M.","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel S.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne L.","family":"Ireland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"issue":"12","key":"pone.0244784.ref001","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2460\/ajvr.2005.66.2065","article-title":"Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses","volume":"66","author":"D McFarlane","year":"2005","journal-title":"Am J Vet Res"},{"issue":"1","key":"pone.0244784.ref002","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.2042-3306.2012.00578.x","article-title":"Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses","volume":"45","author":"TW McGowan","year":"2013","journal-title":"Equine Vet J"},{"issue":"1","key":"pone.0244784.ref003","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1354\/vp.45-1-26","article-title":"Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction","volume":"45","author":"MA Miller","year":"2008","journal-title":"Vet Pathol"},{"key":"pone.0244784.ref004","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.arr.2007.02.001","article-title":"limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease","volume":"6","author":"McFarlane D. Advantages","year":"2007","journal-title":"Ageing Res Rev"},{"issue":"12","key":"pone.0244784.ref005","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.2460\/ajvr.2005.66.2055","article-title":"Agreement in histologic assessments of the pituitary pars intermedia in aged horses","volume":"66","author":"D McFarlane","year":"2005","journal-title":"Am J Vet Res"},{"issue":"2","key":"pone.0244784.ref006","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2826.2005.01277.x","article-title":"Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction","volume":"17","author":"D McFarlane","year":"2005","journal-title":"J Neuroendocrinol"},{"issue":"6","key":"pone.0244784.ref007","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/030098589902700606","article-title":"Immunocytochemical demonstration of proopiomelanocortin-derived peptides in pituitary adenomas of the pars intermedia in horses","volume":"27","author":"M Heinrichs","year":"1990","journal-title":"Vet Pathol"},{"issue":"1","key":"pone.0244784.ref008","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cveq.2010.12.007","article-title":"Equine Pituitary Pars Intermedia Dysfunction","volume":"27","author":"D. McFarlane","year":"2011","journal-title":"Vet Clin North Am Equine Pract"},{"key":"pone.0244784.ref009","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0749-0739(02)00018-4","article-title":"Pituitary pars intermedia dysfunction: equine Cushing\u2019s disease","volume":"18","author":"HC Schott","year":"2002","journal-title":"Vet Clin North Am Equine Pract"},{"key":"pone.0244784.ref010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tvjl.2018.03.002","article-title":"Epidemiology of pituitary pars intermedia dysfunction: a systematic literature review of clinical presentation, disease prevalence and risk factors","volume":"235","author":"JL Ireland","year":"2018","journal-title":"Vet J"},{"issue":"4","key":"pone.0244784.ref011","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1939-1676.2006.tb01816.x","article-title":"Evaluation of the combined dexamethasone suppression\/thyrotropin-releasing hormone stimulation test for detection of pars intermedia pituitary adenomas in horses","volume":"20","author":"N Frank","year":"2006","journal-title":"J Vet Intern Med"},{"issue":"1","key":"pone.0244784.ref012","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.2042-3306.2012.00575.x","article-title":"Evaluation of basal plasma \u03b1-melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses","volume":"45","author":"TW McGowan","year":"2013","journal-title":"Equine Vet J"},{"issue":"2","key":"pone.0244784.ref013","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/vr.139.2.41","article-title":"Montoya J a. Pergolide treatment for Cushing\u2019s syndrome in a horse","volume":"139","author":"MC Mu\u00f1oz","year":"1996","journal-title":"Vet Rec"},{"key":"pone.0244784.ref014","first-page":"141","article-title":"Freedom of Information Summary Corrected Original New Animal Drug Application Prascend Tablets Pergolide Mesylate","year":"2011","journal-title":"NADA"},{"issue":"1","key":"pone.0244784.ref015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1023\/B:VERC.0000045368.38959.8b","article-title":"Equine cushing-like syndrome: Diagnosis and therapy in two cases","volume":"28","author":"M Sgorgini","year":"2004","journal-title":"Vet Res Commun"},{"issue":"11","key":"pone.0244784.ref016","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.nmd.2006.07.019","article-title":"Myopathy in horses with pituitary pars intermedia dysfunction (Cushing\u2019s disease)","volume":"16","author":"M Aleman","year":"2006","journal-title":"Neuromuscul Disord"},{"issue":"11","key":"pone.0244784.ref017","doi-asserted-by":"crossref","first-page":"451456","DOI":"10.1111\/j.1751-0813.2012.00997.x","volume":"90","author":"CW Spelta","year":"2012","journal-title":"Aust Vet J"},{"issue":"4","key":"pone.0244784.ref018","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1939-1676.2012.00932.x","article-title":"Diagnostic frequency, response to therapy, and long-term prognosis among horses and ponies with pituitary par intermedia dysfunction","volume":"26","author":"BW Rohrbach","year":"1993\u20132004","journal-title":"J Vet Intern Med"},{"key":"pone.0244784.ref019","first-page":"154","article-title":"Low-dose pergolide mesylate treatment for equine hypophyseal adenomas","volume":"41","author":"DF Peters","year":"1995","journal-title":"Proc Am Assoc Equine Pr"},{"key":"pone.0244784.ref020","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)02351-5","article-title":"Relation between agendas of the research community and the research consumer","volume":"355","author":"D Tallon","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"pone.0244784.ref021","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/13563890122209847","article-title":"Investigating consumer perspectives on evaluating health technologies","volume":"7","author":"S Oliver","year":"2001","journal-title":"Evaluation"},{"issue":"6990","key":"pone.0244784.ref022","doi-asserted-by":"crossref","first-page":"13151318","DOI":"10.1136\/bmj.310.6990.1315","article-title":"What do I want from health research and researchers when I am a patient?","volume":"310","author":"I. Chalmers","year":"1995","journal-title":"BMJ"},{"issue":"6990","key":"pone.0244784.ref023","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1136\/bmj.310.6990.1318","article-title":"How can health service users contribute to the NHS research and development programme?","volume":"310","author":"SR Oliver","year":"1995","journal-title":"BMJ"},{"issue":"7129","key":"pone.0244784.ref024","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/bmj.316.7129.463","article-title":"Lay perspectives: advantages for health research","volume":"316","author":"VA Entwistle","year":"1998","journal-title":"BMJ"},{"key":"pone.0244784.ref025","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(10)60712-X","article-title":"The James Lind Alliance: Tackling research mismatches","volume":"376","author":"S Petit-Zeman","year":"2010","journal-title":"Lancet"},{"key":"pone.0244784.ref026","unstructured":"jla.nihr.ac.uk\/priority-setting-partnerships\/ [Internet]. James Lind Alliance: The PSPs; c2017 [cited 2017 May 08] Available from: http:\/\/www.jla.nihr.ac.uk\/priority-setting-partnerships\/."},{"issue":"3","key":"pone.0244784.ref027","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2753.2009.01262.x","article-title":"Identifying and prioritizing uncertainties: Patient and clinician engagement in the identification of research questions","volume":"16","author":"G Elwyn","year":"2010","journal-title":"J Eval Clin Pract"},{"issue":"7","key":"pone.0244784.ref028","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1464-410X.2011.10609.x","article-title":"The James Lind alliance approach to priority setting for prostate cancer research: An integrative methodology based on patient and clinician participation","volume":"108","author":"A Lophatananon","year":"2011","journal-title":"BJU Int"},{"key":"pone.0244784.ref029","unstructured":"jla.nihr.ac.uk [internet]. The James Lind Alliance Guidebook; c2016 [cited 2017 May 08]. Available from: www.jla.nihr.ac.uk\/jla-guidebook\/."},{"issue":"3","key":"pone.0244784.ref030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/JAC.0b013e3181e62cda","article-title":"The James Lind alliance: Tackling treatment uncertainties together","volume":"33","author":"K. Cowan","year":"2010","journal-title":"J Ambul Care Manage"},{"key":"pone.0244784.ref031","first-page":"1","volume-title":"Handbook of Health Services Research Methods; Investigation, measurement and analysis","author":"A Bowling","year":"2005","edition":"1"},{"key":"pone.0244784.ref032","unstructured":"Dean R. Identification of research priorities of veterinary surgeons and cat owners with regard to the treatment of Chronic Kidney Disease (CKD) in Cats [Masters Thesis]. University of Oxford; 2014."},{"key":"pone.0244784.ref033","unstructured":"Crowe S. James Lind Alliance Priority Setting Partnerships Setting priorities for treatment uncertainties\u2014a review of methods [Internet]. James Lind Alliance; 2009 [cited 2017 Jun 06]. Available from: http:\/\/www.jla.nihr.ac.uk\/news-and-publications\/downloads\/review-of-priority-setting-methods-sally-crowe.pdf."},{"key":"pone.0244784.ref034","unstructured":"kwiksurveys.com [Internet]. A survey maker, for individuals and teams; c2017 [cited 2017 Nov 12]. Available from: https:\/\/kwiksurveys.com\/."},{"key":"pone.0244784.ref035","unstructured":"talkaboutlaminitis.co.uk [Internet]. Let\u2019s talk about laminitis; c2017 [cited 2017 Nov 20]. Available from: https:\/\/www.talkaboutlaminitis.co.uk\/careandconnect."},{"key":"pone.0244784.ref036","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3138\/jvme.1111.109R","article-title":"Searching the veterinary literature: a comparison of the coverage of veterinary journals by nine bibliographic databases","volume":"39","author":"DJ Grindlay","year":"2016","journal-title":"J Vet Med Educ"},{"key":"pone.0244784.ref037","first-page":"126","article-title":"The Nominal Group Technique: A useful consensus methodology in physiotherapy research","volume":"32","author":"M Potter","year":"2004","journal-title":"New Zeal J Physiother"},{"key":"pone.0244784.ref038","unstructured":"Augustana.ca [internet] Random Number Genorator; c2004 [cited 2017 Dec 01]. Available from: http:\/\/www.augustana.ca\/~mohrj\/algorithms\/randpick.html."},{"key":"pone.0244784.ref039","first-page":"530","article-title":"Future research into the treatment of vitiligo: where should our priorities lie?","author":"on behalf of the vitiligo priority setting partnership","year":"2011","journal-title":"Results of the vitiligo priority setting partnership"},{"key":"pone.0244784.ref040","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/j.1464-5491.2012.03755.x","article-title":"Research: Health Economics Setting research priorities for Type 1","author":"R Gadsby","year":"2012","journal-title":"diabetes"},{"issue":"1","key":"pone.0244784.ref041","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.2042-3306.2010.00145.x","article-title":"A cross-sectional study of geriatric horses in the United Kingdom. Part 1: Demographics and management practices","volume":"43","author":"JL Ireland","year":"2011","journal-title":"Equine Vet J"},{"issue":"4","key":"pone.0244784.ref042","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2746\/042516407X177538","article-title":"A survey of horse owners in Great Britain regarding horses in their care. Part 1: Horse demographic characteristics and management","volume":"39","author":"JW Hotchkiss","year":"2007","journal-title":"Equine Vet J"},{"key":"pone.0244784.ref043","unstructured":"cebm.net [internet] Oxford Centre for Evidence-based Medicine\u2013CEBM Levels of Evidence; c2009 [cited 2017 Oct 02]. Available from: https:\/\/www.cebm.net\/2016\/05\/ocebm-levels-of-evidence\/."},{"issue":"1","key":"pone.0244784.ref044","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/eve.12142","article-title":"EVE and EVJ online collection of equine endocrinology: Recent and future directions; a great start but still a long way to go","volume":"26","author":"CM Marr","year":"2014","journal-title":"Equine Vet Educ"},{"issue":"12","key":"pone.0244784.ref045","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S2213-8587(17)30324-8","article-title":"Top ten research priorities for type 2 diabetes: results from the Diabetes UK-James Lind Alliance Priority Setting Partnership","volume":"5","author":"S Finer","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"pone.0244784.ref046","doi-asserted-by":"crossref","first-page":"170193","DOI":"10.1098\/rsos.170193","article-title":"Making better decisions in groups","volume":"4","author":"D Bang","year":"2017","journal-title":"R Soc Open Sci"},{"issue":"2","key":"pone.0244784.ref047","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.2042-3292.1997.tb01308.x","article-title":"Equine Cushing\u2019s disease","volume":"9","author":"JH van der Kolk","year":"1997","journal-title":"Equine Vet Edu"},{"key":"pone.0244784.ref048","first-page":"921","article-title":"Treatment of hypophysial adenomas","volume":"16","author":"J. Beech","year":"1994","journal-title":"Compend Contin Educ"},{"key":"pone.0244784.ref049","first-page":"742","article-title":"Treatment with pergolide or cyproheptadine of Pituitary Pars Intermedia Dysfunction (Equine Cushing\u2019s Disease)","volume":"16","author":"MT Donaldson","year":"2002","journal-title":"J Vet Intern Med"},{"issue":"7","key":"pone.0244784.ref050","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2746\/042516402776250333","article-title":"Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing\u2019s disease with cyproheptadine or pergolide","volume":"34","author":"GA Perkins","year":"2002","journal-title":"Equine Vet J"},{"key":"pone.0244784.ref051","unstructured":"Schott II HC, Rapson JR, Marteniuk J V, Wismer S. Long-term response of equids with pituitary pars intermedia dysfunction to treatment with pergolide. Proc 60th Annu Conv Am Assoc Equine Pract Salt Lake City, Utah, USA, December 6\u201310 2014. 2014;329."},{"issue":"4","key":"pone.0244784.ref052","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/evj.13041","article-title":"Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction","volume":"51","author":"R Horn","year":"2019","journal-title":"Equine Vet J"},{"issue":"1","key":"pone.0244784.ref053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1939-1676.1996.tb02016.x","article-title":"Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism","volume":"10","author":"L Cou\u00ebtil","year":"1996","journal-title":"J Vet Intern Med"},{"issue":"3","key":"pone.0244784.ref054","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2460\/javma.231.3.417","article-title":"Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia","volume":"231","author":"J Beech","year":"2007","journal-title":"J Am Vet Med Assoc"},{"key":"pone.0244784.ref055","first-page":"386","article-title":"Characteristics of plasma adrenocorticotropin, \u03b2\u2010endorphin and \u03b1\u2010melanocyte stimulating hormone as diagnostic tests for pituitary pars intermedia dysfunction in the horse","volume":"17","author":"ML Horowitz","year":"2003","journal-title":"J Vet Intern Med"},{"issue":"1","key":"pone.0244784.ref056","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1751-0147-50-6","article-title":"Circulating beta-endorphin, adrenocorticotrophic hormone and cortisol levels of stallions before and after short road transport: stress effect of different distances","volume":"50","author":"E Fazio","year":"2008","journal-title":"Acta Vet Scand"},{"issue":"1","key":"pone.0244784.ref057","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.rvsc.2011.05.013","article-title":"Gutierrez-Panizo C, Clavel JG, Illera JC. Cortisol, adrenocorticotropic hormone, serotonin, adrenaline and noradrenaline serum concentrations in relation to disease and stress in the horse","volume":"93","author":"I Ayala","year":"2012","journal-title":"Res Vet Sci"},{"issue":"5","key":"pone.0244784.ref058","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1111\/jvim.15620","article-title":"Cortisol and adrenocorticotropic hormone concentrations in horses with systemic inflammatory response syndrome","volume":"33","author":"AJ Stewart","year":"2019","journal-title":"J Vet Intern Med"},{"key":"pone.0244784.ref059","article-title":"Setting research priorities to improve the health of children and young people with neurodisability: a British Academy of Childhood Disability-James Lind Alliance Research Priority Setting Partnership","volume":"5","author":"C Morris","year":"2015","journal-title":"Br Med J"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0244784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T19:40:32Z","timestamp":1724182832000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0244784"}},"subtitle":[],"editor":[{"given":"Samy A.","family":"Azer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0244784","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,4]]}}}